Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00203060
Status:
COMPLETED
Last Update Posted:
2011-04-12
First Post:
2005-09-13
Brief Title:
Effectiveness Tolerability and Safety of Rasagiline in Early Parkinsons Disease Patients Not Treated With Levodopa
Sponsor:
Teva Neuroscience Inc
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
A Multicenter Double-Blind Placebo-Controlled Parallel Group Phase III Clinical Trial For The Efficacy Tolerability And Safety Of Two Doses Of Rasagiline Mesylate In Early Parkinsons Disease PD Patients Not Treated With Levodopa
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study to look at the effectiveness tolerability and safety of two doses of Study Medication in Early Parkinsons Disease PD Patients who have not been treated with Levodopa
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None